on behalf of the CATIS investigators BACKGROUND Optimal blood pressure (BP) levels during acute ischemic stroke have not been established. We studied associations between systolic BP trajectories during acute phase and subsequent clinical outcomes among patients with ischemic stroke.
Stroke is a major cause of mortality and a leading cause of serious, long-term disability worldwide. 1 Elevated blood pressure (BP) is common during acute ischemic stroke 2, 3 and predicts a poor prognosis. 4, 5 However, several large randomized clinical trials have documented that immediate BP lowering during acute ischemic stroke does not reduce death or major disability in patients with elevated BP levels. [6] [7] [8] In the China Antihypertensive Trial in Acute Ischemic Stroke (CATIS), the mean systolic BP was reduced from 166.7 to 144.7 mm Hg within 24 hours, and to 137.3 mm Hg at day 7 after randomization among patients with acute ischemic stroke. 7 Nevertheless, patients who received antihypertensive treatment did not reduce death and major disability at 3 months compared to those who did not. 7 Therefore, optimal BP levels during acute ischemic stroke have not been established. 9, 10 Elevated BP during acute ischemic stroke is a heterogeneous phenotype that could reflect uncontrolled or undiagnosed hypertension or an early hypertensive response to physical and psychological stresses from brain ischemia. 11 Furthermore, BP decreases during the natural course of acute ischemic stroke, and responses to antihypertensive treatment vary significantly among patients with ischemic stroke. 7, 10 To the best of our knowledge, there is no study that has examined the trajectories of BP changes during acute ischemic stroke and the prognosis of clinical outcomes among patients with ischemic stroke. We conducted a post hoc analysis to identify subgroups of ischemic stroke patients with similar trajectories of BP changes during the acute phase, and to examine the associations between BP trajectories and adverse clinical outcomes among the CATIS participants.
METHODS

Study participants
The CATIS study was a multicenter randomized clinical trial conducted in 26 hospitals across China between August 2009 and May 2013. The trial design, methods, and main outcomes have been published previously. 7 In brief, a total of 4,071 patients aged ≥22 years with ischemic stroke confirmed by computed tomography or magnetic resonance imaging of the brain within 48 hours of symptom onset, and with a systolic BP between 140 and 220 mm Hg were recruited into the trial. Patients with a systolic BP ≥ 220 mm Hg and/ or diastolic BP ≥120 mm Hg, severe heart failure, acute myocardial infarction or unstable angina, atrial fibrillation, aortic dissection, cerebrovascular stenosis, resistant hypertension, deep coma, or intravenous thrombolytic therapy were excluded from the trial. The CATIS participants were randomly assigned to receiving antihypertensive treatment or not receiving antihypertensive treatment. In the treatment group, we aimed at lowering systolic BP by 10%-25% within the first 24 hours after randomization, achieving a systolic BP < 140 and diastolic BP < 90 mm Hg within 7 days, and maintaining this level of BP control during the remainder of a patient's hospitalization. 7 In the control group, all home antihypertensive medications were discontinued after randomization. There was no difference between the intervention and control groups regarding to co-treatments. Patients in both groups were prescribed antihypertensive medication at their hospital discharge according to clinical guidelines. 7 This study evaluated the impact of BP trajectories during the first week after stroke onset on clinical outcomes at 3 and 24 months. Therefore, the dataset for this analysis was composed of 4,016 participants who survived the first week after ischemic stroke onset.
The CATIS study was approved by the institutional review boards at Tulane University in the United States and Soochow University in China, as well as by ethical committees at the 26 participating hospitals. Written consent was obtained from all study participants.
BP measurement
Three BP measurements were obtained at baseline, every 2 hours for the first 24 hours after randomization, every 4 hours during the second and third days, and every 8 hours thereafter until hospital discharge or death. BPs were measured by trained nurses using a standard mercury sphygmomanometer and 1 of 4 cuff sizes (pediatric, regular adult, large adult, or thigh) based on participants' arm circumferences with participants in supine position according to standard protocol as recommended by the American Heart Association. 12 The mean of the 3 BP measurements at each of the 36 time points was used to fit BP trajectories.
Construction of BP trajectories
Latent variable mixture modeling was used to identify subgroups that share a similar underlying trajectory of systolic BP during the first 7 days after stroke onset and was implemented by the SAS Proc Traj procedure. 13, 14 Latent variable mixture modeling is an emerging statistical approach that models heterogeneous longitudinal data by classifying individuals into groupings with similar patterns, called latent classes. 13 We fitted all trajectory models in quadratic form, starting with a 1-trajectory model, and then fitted models up to the optimal number of trajectories by comparing the Bayesian Information Criterion for each set of trajectories. Hours from randomization to BP measurements (36 time points) were used as the timescale. Once we had identified that the model with 5 trajectories fitted best and had a sufficient number of participants in each trajectory, we compared the model fit with different forms. The final models have 5 trajectories in cubic form for both systolic and diastolic BP. Participants were classified into trajectory groups with excellent discrimination. The mean probability of final group membership ranged from 90.3% to 97.3% for systolic BP trajectories and 88.2% to 94.9% for diastolic BP trajectories.
Outcome assessment
After hospital discharge, the CATIS participants were followed up in person at months 3, 12, and 24 by trained neurologists and study nurses. The primary study outcome was a combination of death and major disability at months 3 and 24. Major disability was defined as a score of 3-5 on the modified Rankin Scale. Scores on the modified Rankin Scale ranged from 0 to 6, with a score of 0 indicating no symptoms, a score of 5 indicating severe disability, and a score of 6 indicating death. 15 The secondary outcomes included recurrent stroke, cardiovascular disease (i.e., cardiovascular deaths, nonfatal stroke, nonfatal myocardial infarction, hospitalized and treated angina, and hospitalized and treated heart failure), and all-cause mortality at months 3 and 24. Clinical events were identified at in-person interviews, and hospital data were obtained for centralized adjudicated review. The outcome assessment committee, blinded to treatment assignment, reviewed and adjudicated recurrent stroke and cardiovascular events based on the criteria established in the Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial. 16 
Statistical analysis
Baseline characteristics according to BP trajectories were presented as percentages for categorical variables and means and SDs or medians and interquartile ranges for continuous variables. Chi-square and 1-way analysis of variance tests were used to compare categorical and continuous variables, respectively, across BP trajectories. Logistic regression was used to examine the associations between BP trajectories and clinical outcomes at 3 months, as well as the composite outcome of mortality and major disability at 24 months adjusting for age, sex, study sites, stroke subtypes, antihypertensive intervention, smoking, body mass index, history of hypertension, diabetes, dyslipidemia, and modified Rankin score at discharge. Cox proportional hazards models were used to investigate the associations of BP trajectories with hazards of recurrent stroke, cardiovascular disease, and all-cause mortality over the 24-month follow-up. Proportional hazard assumption was verified in Kaplan-Meier curves analyses. In all analyses, the highest BP trajectory (trajectory 1) was used as reference group. BP trajectories were also evaluated by subtypes of ischemic stroke. We focused on systolic BP trajectories in analyses because similar results were found for diastolic BP. Interactions between BP trajectories and trial interventions were not significant for all study outcomes (Supplementary  Tables 1 and 2 ). Therefore, we presented the study results in overall participants.
Odds ratios (ORs), hazard ratios, 95% confidence intervals (CIs), and 2-sided P values were presented. P values < 0.05 were considered statistically significant. Data analyses were performed using SAS, version 9.4 (SAS Institute, Cary, NC).
RESULTS
BP trajectories and study participants
Five systolic BP trajectories were identified ( Figure 1 ). Trajectory 1 (high systolic BP) included 12.9% of the CATIS participants with systolic BP started at approximately 180 mm Hg and gradually reduced to 160 mm Hg in 7 days. Trajectory 2 (high-to-moderate-low systolic BP) included 12.7% participants with a high systolic BP at baseline that quickly decreased to 140 mm Hg within 3 days and remained at or below this level afterward. Trajectory 3 (moderate-high systolic BP) included 24.2% participants with systolic BP between 150 and 160 mm Hg during the first 7 days. Trajectory 4 (moderate-low systolic BP) included 33.8% participants with systolic BP starting at around 150 mm Hg and gradually decreasing to <140 mm Hg during the first 7 days. Trajectory 5 (low systolic BP) included 16.4% participants with systolic BP below 130 mm Hg after day 1. Systolic BP was reduced more or less among all BP trajectories during the first 7 days among patients in both the intervention and control groups ( Supplementary Figures 1 and 2 ). Antihypertensive treatment successfully shifted patients from higher BP trajectories to lower BP trajectories. For example, there were more patients in trajectory 2 (343 vs. 158) and fewer patients in trajectory 1 (141 vs. 366) in the intervention group compared to those in the control group (Supplementary Tables 1 and 2 ).
The majority (77.2%) of the stroke subtypes were thrombotic, followed by lacunar (21.7%) and embolic (4.2%) subtypes. Age and sex distributions were similar across the 5 systolic BP trajectories ( Table 1) . As expected, participants who received antihypertensive treatment were more likely to be in trajectories with lower mean systolic BP during the intervention. Participants in high-to-moderate-low and moderate-high systolic BP trajectories had higher National Institutes of Health stroke scores (NIHSS) than those in the remaining 3 trajectories. Participants in the low systolic BP trajectory were less likely to have a history of hypertension or use of antihypertensive medication before randomization.
BP trajectories and major clinical outcomes at 3 months
Event rates for the composite outcome of death and major disability, recurrent stroke, cardiovascular disease, and all-cause mortality at month 3 were significantly higher among patients in the high systolic BP trajectory (Table 2) . For example, compared to patients in the high trajectory, multivariable-adjusted ORs (95% CI) for the composite Three blood pressure measurements were obtained at baseline, every 2 hours for the first 24 hours after randomization, every 4 hours during the second and third days, and every 8 hours thereafter until hospital discharge or death. The mean of 3 systolic blood pressure measurements at each of the 36 time points was used to fit trajectories.
outcome of death and major disability were 0.81 (0.53-1.25), 0.57 (0.39-0.81), 0.45 (0.31-0.65), and 0.45 (0.29-0.71) among patients in high-to-moderate-low, moderate-high, moderate-low, and low trajectories, respectively.
Patients in the moderate-low trajectory group had the lowest risk of all clinical outcomes. Compared to the high systolic BP trajectory, multivariable-adjusted ORs (95% CI) associated with the moderate-low trajectory were 0.21 (0.09-0.48), 0.22 (0.11-0.42), 0.24 (0.11-0.55), and 0.23 (0.13-0.40) for recurrent stroke, cardiovascular disease, all-cause mortality, and the composite outcome of cardiovascular disease and deaths, respectively. Patients in the high-to-moderate-low systolic BP trajectory had significantly lower risk of these clinical outcomes compared to high trajectory. When stratified by stroke subtypes, lowest risks for the composite outcome of death and major disability were observed in the moderate-low systolic BP trajectory group for thrombotic (OR = 0.51, 95% CI: 0.39-0.76) and lacunar subtypes (OR = 0.38, 95% CI: 0.19-0.75), and in the low systolic BP trajectory group for the embolic subtype (OR = 0.34, 95% CI: 0.09-1.34) (Supplementary Table 5 ). Although not statistically different, ORs of the composite outcome of death and major disability associated with the high-to-moderate-low systolic BP trajectory were on opposite directions between the intervention and control groups ( Supplementary Tables 1 and 2 ). The high-tomoderate-low systolic BP trajectory was associated with higher odds (OR = 1.14, 95% CI: 0.57-2.29) of the composite outcome compared to the high trajectory in the intervention group, but lower odds (OR = 0.69, 95% CI: 0.37-1.29) in the control group. Meanwhile, the high-to-moderate-low systolic BP trajectory was associated with lower odds of allcause mortality in the intervention group (OR = 0.08, 95% CI: 0.02-0.36) compared to in the control group (OR = 0.24, 95% CI: 0.02-2.41). 
BP trajectories and major clinical outcomes in 2 years
The 2-year cumulative rates of the composite outcome of death and major disability were the highest among patients in the high systolic BP trajectory group and the lowest in the moderate-low trajectory group (Table 3) . Compared to the high systolic BP trajectory, the multivariable-adjusted ORs (95% CI) of the composite outcome of death and major disability were 0.81 (0.55-1.19), 0.87 (0.63-1.21), 0.52 (0.37-0.72), and 0.56 (0.37-0.85) for patients in high-to-moderatelow, moderate-high, moderate-low, and low trajectories, respectively. A similar pattern was observed in all stroke subtypes (Supplementary Table 6 ).
The cumulative hazard rates of recurrent stroke, cardiovascular disease, all-cause mortality, and the composite outcome of cardiovascular disease and CI, confidence interval; HR, hazard ratio for outcomes except for death and major disability; OR, odds ratio of death and major disability. a Adjusted for age, sex, study sites, stroke subtypes, antihypertensive intervention, smoking, body mass index, history of hypertension, diabetes, dyslipidemia, and modified Rankin score at discharge. deaths were the lowest in the moderate-low systolic BP trajectory group and the highest in the high trajectory group (Figure 2 ). The hazard rates of these outcomes for individuals in the moderate-low trajectory were 0.63 (0.44-0.90), 0.57 (0.42-0.79), 0.45 (0.32-0.66), and 0.57 (0.43-0.74) compared to those in the high systolic BP trajectory. Individuals in high-to-moderate-low had similar hazard rates as those in the moderate-low trajectories. In stroke subtype analyses, participants in the moderate-low trajectory had the lowest hazard rates for clinical outcomes, except for all-cause mortality and the composite outcome of cardiovascular disease and deaths among patients with embolic stroke (Supplementary Table 6 ). Embolic stroke patients with the high-tomoderate-low systolic BP trajectory had the lowest risk of all-cause mortality and the composite outcome of cardiovascular disease and deaths, respectively.
In a sensitivity analysis adjusting for NIHSS instead of the modified Rankin Scale score, the results are consistent (Supplementary Tables 7 and 8 ).
DISCUSSION
These study findings help advance our understanding of the association of BP during acute ischemic stroke with clinical outcomes in several aspects. First, patients with the highest systolic BP, averaging 175.8 mm Hg during the first 24 hours and 166.5 mm Hg during days 2-7 (trajectory 1) had the highest risk for major disability, death, recurrent stroke, and cardiovascular disease. Second, patients who experienced a rapid BP reduction from approximately 180 mm Hg to <140 mm Hg during the first 3 days (trajectory 2) had reduced risks of clinical outcomes (nonsignificant for the composite outcome of death and major disability) compared to those without rapid reduction (trajectory 1). Third, patients with moderate-low systolic BP, averaging 139.3 mm Hg (trajectory 4) during days 2-7 had the lowest risk of adverse clinical outcomes.
Elevated BP in the acute phase occurs in about 75% of all ischemic stroke patients. 2, 3 Positive, inverse, and U-shaped associations between BP levels during acute ischemic stroke and adverse clinical outcomes have been reported. 4 In the Third International Stroke Trial of 3,035 patients with acute ischemic stroke, a high baseline BP was associated with higher numbers of early adverse events and deaths while a larger decline in BP and the use of antihypertensive treatment during the first 24 hours were associated with a reduced risk of poor outcome. 4 In contrast, Wohlfahrt et al., 9 in a study of 532 patients with first acute ischemic stroke, reported that a systolic BP < 140 mm Hg at admission was associated with increased all-cause mortality compared to those with a systolic BP ≥ 140 mm Hg. Furthermore, a U-shaped relationship was found between baseline systolic BP and both early death and late death or dependency among 17,398 patients with acute ischemic stroke from the International Stroke Trial. 18 Our study found that patients with a systolic BP > 180 mm Hg at admission and >160 mm Hg during the first 7 days had a significantly increased risk of major disability, death, and cardiovascular disease compared to those with a lower BP. It is worth noting that participants in the trajectory 1 had a higher proportion of preexisting hypertension. Given that hypertension is an important risk factor for cardiovascular disease and mortality, different proportions of patients with preexisting hypertension may confound the association between BP trajectories and major clinical outcomes. After adjusting for the history of hypertension in the multivariable models, however, trajectory 1 was still significantly associated with the higher risks of important clinical outcomes. In addition, the moderate-high trajectory (trajectory 3) had similar proportion of patients with preexisting hypertension (80.8% vs. 82.3%), but lower risk for cardiovascular disease. Our study findings support the notion that very high BP during the acute phase of ischemic stroke increases the risk of adverse clinical outcomes. It has been observed that BP decreases spontaneously during the natural course of acute ischemic stroke. 21, 22 In our study, systolic BP was reduced during the first 7 days among all BP trajectories among patients in the intervention and control groups. Patients who experienced a rapid systolic BP reduction (trajectory 2, from approximately 180 mm Hg at baseline to 140 mm Hg within 3 days) had a significantly lower risk of recurrent stroke, all-cause mortality, cardiovascular disease, and the combined outcome of cardiovascular disease and allcause mortality compared to those with consistently high BP (trajectory 1). In addition, the risk of adverse clinical events in the rapid BP reduction group (trajectory 2) was similar to that of patients with moderate-low systolic BP (trajectory 4). Antihypertension medication shifted patients from trajectory 1 to trajectory 2 in the intervention group. Interestingly, although not statistically different, trajectory 2 was associated with a higher risk for the composite outcome of death and major disability in the intervention group, but a lower risk for the composite outcome in the control group. This may be because shifting patients from trajectories 1 to 2 associated with antihypertensive treatment reduced all-cause mortality but increased major disability. This is evidenced by the result that trajectory 2 in the intervention group was associated with much lower risk for all-cause mortality compared to that in the control group. Taken together, these results suggest that lowering BP among acute ischemic stroke patients with a very high BP at admission (i.e., systolic ≥180 mm Hg) to a moderate level, instead of intensive BP control, might reduce risk of adverse clinical outcomes. Previous randomized clinical trials typically included patients with a systolic BP ≥ 140 mm Hg and showed BP lowering in early ischemic stroke had a neutral effect on death or major dependency. 23 The risks of recurrent stroke and cardiovascular disease were lower among patients with moderate-low systolic BP than those among patients with low systolic BP. Previous clinical studies have suggested that dynamic cerebral autoregulation is impaired in the affected hemisphere throughout the first week in acute ischemic stroke. 24 Low BP might diminish collateral flow through arteries that have lost autoregulation and increase the size of the cerebral infarct. 25 Our data suggest that ischemic stroke patients with a systolic BP between 130 and 140 mm Hg during the acute phase after 24 hours might have the most favorable clinical outcomes.
Our study has several strengths. The large sample size of patients with ischemic stroke and extensive number of BP measurements during the acute phase enabled us to accurately characterize subgroups that share a similar underlying BP trajectory. During the first week after onset, BPs were measured at 36 time points, and at each time point, BP was measured 3 times. In addition, stringent quality control measures were used in data collection in our study. We achieved a follow-up rate of 97.7% over 2 years. Certain limitations should also be acknowledged. First, this analysis was limited by its observational nature: it is unclear whether patient with consistently high BP, particularly those in the intervention group, was due to more devastating stroke. However, baseline NIHSS in this group was even lower than scores in the high-to-moderate-low and moderate-high groups. More importantly, adjusting for baseline NIHSS did not change the associations of systolic BP trajectories with major clinical outcomes. Second, our study examined systolic BP trajectories during the first 7 days and subsequent clinical outcomes. Therefore, we excluded patients who died within the first week after stroke onset. In addition, the CATIS included stroke patients within 48 hours of symptom onset. BP rapidly declines within the first few days of stroke onset. Therefore, trajectory type may be misclassified for patients who were admitted to participating hospitals shortly before 48 hours of symptom onset. However, most of the patients (70%) were hospitalized within 24 hours of symptom onset. Third, this study was not a prespecified analysis. This observational analysis could be influenced by potential biases and confounding factors. Therefore, our study only generates hypotheses for future interventional trials. Fourth, we did not collect data on co-treatments during follow-up after hospital discharge. Therefore, potential group differences related to long-term outcome could not be adjusted. However, both intervention and control groups received usual care from their providers during the follow-up period. Furthermore, as a complex statistical tool, the latent mixed class analysis itself has some limitations and many assumptions. For example, if too few groups are specified, a unique subgroup may get overlooked. However, we have identified as many as 5 subgroups, and the mean probability of final group membership was very high in this study, ranging from 90.3% to 97.3%. Finally, this study was a secondary analysis to the CATIS trial, in which strict exclusion criteria have been applied. In addition, most participants had minor stroke. This limits the generalizability of our findings to all acute ischemic strokes.
In conclusion, our study identified 5 trajectories of systolic BP during the acute phase among patients with ischemic stroke and elevated BP. Compared to patients with a consistently high systolic BP (>160 mm Hg), those with moderatelow or reduced to moderate-low systolic BP (<140 mm Hg) during acute ischemic stroke had a lower risk of adverse clinical outcomes at 3 and 24 months. Future clinical trials should test whether ischemic stroke patients with systolic BP around 140 mm Hg during acute phase after 24 hours have the most favorable clinical outcomes.
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